PROM1 and cancer: Furthermore, we discovered that a low dose of NU7441 significantly reduced CSC enrichment in drug-resistant cancer cells, as shown by decreased expression of key markers of CSCs (ALDH1A1, KLF4, CD133, Nanog, and SOX9) (Fig. 5D) and diminished sphere formation ability (Fig. 5E).